Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

VLPCOV-01 is a lipid nanoparticle-encapsulated self-amplifying RNA (saRNA) vaccine that expresses a membrane-anchored receptor-binding domain (RBD) derived from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. A phase 1 study of VLPCOV-01 is conducted (jRCT2051210164)....

Descripción completa

Detalles Bibliográficos
Autores principales: Akahata, Wataru, Sekida, Takashi, Nogimori, Takuto, Ode, Hirotaka, Tamura, Tomokazu, Kono, Kaoru, Kazami, Yoko, Washizaki, Ayaka, Masuta, Yuji, Suzuki, Rigel, Matsuda, Kenta, Komori, Mai, Morey, Amber L., Ishimoto, Keiko, Nakata, Misako, Hasunuma, Tomoko, Fukuhara, Takasuke, Iwatani, Yasumasa, Yamamoto, Takuya, Smith, Jonathan F., Sato, Nobuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439244/
https://www.ncbi.nlm.nih.gov/pubmed/37586325
http://dx.doi.org/10.1016/j.xcrm.2023.101134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439244/
https://www.ncbi.nlm.nih.gov/pubmed/37586325
http://dx.doi.org/10.1016/j.xcrm.2023.101134

Ejemplares similares